Roy Chowdhury, Sharmistha
Sadouki, Fethi
Collins, Edward
Keen, Frederick
Bhagi, Ridhi
Lim, Yuan S. J.
Cozma, Silviu L.
Bain, Stephen C.
Article History
Received: 8 December 2023
Accepted: 7 February 2024
First Online: 1 March 2024
Declarations
:
: Sharmistha Roy Chowdhury reports receiving payment for lectures, presentations and/or educational activities from Novo Nordisk, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, and support for attending meetings from Novo Nordisk. Stephen C. Bain reports grants and personal fees from AstraZeneca, Novo Nordisk and Sanofi-Aventis; personal fees from Boehringer Ingelheim, Eli Lilly and Merck Sharp & Dohme; grants from Medscape; expert advice provided to All-Wales Medicines Strategy Group and National Institute for Health and Care Excellence UK. In addition, Stephen C. Bain is an Editorial Board member of Diabetes Therapy. Stephen C. Bain was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Fethi Sadouki and Edward Collins are employees of Novo Nordisk Ltd. Frederick Keen, Ridhi Bhagi, Yuan S. J. Lim, and Silviu L. Cozma have nothing to disclose. Since this manuscript was written, the following authors have changed affiliation: Sharmistha Roy Chowdhury is now affiliated with the University Hospital of Wales, Cardiff and Vale UHB, Cardiff, United Kingdom. Frederick Keen is now affiliated with University Hospital Llandough, Cardiff and Vale UHB, Cardiff, United Kingdom. Yuan Shen Justin Lim is now affiliated with Ipswich Hospital, East Suffolk and North Essex Foundation Trust, Ipswich, United Kingdom.
: This study was assessed using the decision tool on the HRA website [ExternalRef removed]. Ethics committee approval was not required, as the analysis was conducted as part of a service-based evaluation project to examine the effects of semaglutide therapy, which is routine in our local practice. Only de-identified secondary data were used. Approval from the head of department was received.